A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 1978-1984

  Doust, Jenny A ^a   Glasziou, Paul P ^a   Pietrzak, Eva ^a   Dobson, Annette J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; ELECTROCARDIOGRAM; ELECTRONICS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MEDICAL RESEARCH; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ATRIAL NATRIURETIC FACTOR; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN;

EID: 6344294410     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.18.1978     Document Type: Review

References (41)

1. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439-444.
2. Redfield M. Heart failure: an epidemic of uncertain proportions. N Engl J Med. 2002;347:1442-1444.
3. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.
4. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ. 1999; 318:368-372.
5. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829-833.
6. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J. 1999;20:447-455.
7. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1353.
8. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ. 2003;326:196.
9. Baughman KL. B-type natriuretic peptide: a window to the heart. N Engl J Med. 2002;347:158-159.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
11. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993; 12:1293-1316.
12. Pepe M. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, England: Oxford University Press; 2003:108.
13. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
14. Bettencourt P, Ferreira A, Pardal-Oliveira N, et al. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol. 2000;23:921-927.
15. Choy AM, Darbar D, Lang CC, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994;72:16-22.
16. Valli N, Georges A, Corcuff JB, Barat JL, Bordenave L. Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data. Clin Chim Acta. 2001;306:19-26.
17. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002; 288:1252-1259.
18. Hutcheon SD, Gillespie ND, Struthers AD, McMurdo ME. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing. 2002;31:295-301.
19. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ. 2000;320:985-986.
20. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ. 2000;320:906-908.
21. McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fall. 2002;4:479-483.
22. Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fall. 2000;6:194-200.
23. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-994.
24. Luchner A, Burnett JC Jr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121-1128.
25. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111:274-279.
26. Osca J, Quesada A, Arnau MA, et al. Brain natriuretic peptide: diagnostic value in heart failure [in Spanish]. Rev Esp Cardiol. 2002;55:7-15.
27. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440-444.
28. Hobbs F, Davis R, Roalfe A, Hare R, Davies M, Kenkre J. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study In representative and high risk community populations. BMJ. 2002;324:1498-1500.
29. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
30. Castro A, Dias P, Pereira M, et al. Type B natriuretic peptide in the diagnosis of heart failure with preserved systolic function [in Portuguese]. Rev Port Cardiol. 2001;20:1109-1113.
31. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595-601.
32. Boyko EJ. Re: "Meta-analysis of Pap test accuracy." Am J Epidemiol. 1996;143:406-407.
33. Kalra PR, Struthers AD. More evidence for bedside BNP in heart failure assessment. Int J Cardiol. 2002;86:149-152.
34. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med. 2001;39:446-450.
35. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422.
36. Cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
37. Pfeffer MA, Braunwald E, Moye LA, et al, SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
38. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe congestive heart failure. N Engl J Med. 2001;344:1651-1658.
39. Cheitlin MD. Can clinical evaluation differentiate diastolic from systolic heart failure? if so, is it important? Am J Med. 2002;112:496-497.
40. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
41. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999; 138:1126-1132.